International Journal of Molecular Sciences (Aug 2022)

Vaccine for Diabetes—Where Do We Stand?

  • Dinesh Kumar Chellappan,
  • Richie R. Bhandare,
  • Afzal B. Shaik,
  • Krishna Prasad,
  • Nurfatihah Azlyna Ahmad Suhaimi,
  • Wei Sheng Yap,
  • Arpita Das,
  • Pradipta Banerjee,
  • Nandini Ghosh,
  • Tanner Guith,
  • Amitava Das,
  • Sarannya Balakrishnan,
  • Mayuren Candasamy,
  • Jayashree Mayuren,
  • Kishneth Palaniveloo,
  • Gaurav Gupta,
  • Sachin Kumar Singh,
  • Kamal Dua

DOI
https://doi.org/10.3390/ijms23169470
Journal volume & issue
Vol. 23, no. 16
p. 9470

Abstract

Read online

Diabetes is an endocrinological disorder with a rapidly increasing number of patients globally. Over the last few years, the alarming status of diabetes has become a pivotal factor pertaining to morbidity and mortality among the youth as well as middle-aged people. Current developments in our understanding related to autoimmune responses leading to diabetes have developed a cause for concern in the prospective usage of immunomodulatory agents to prevent diabetes. The mechanism of action of vaccines varies greatly, such as removing autoreactive T cells and inhibiting the interactions between immune cells. Currently, most developed diabetes vaccines have been tested in animal models, while only a few human trials have been completed with positive outcomes. In this review, we investigate the undergoing clinical trial studies for the development of a prototype diabetes vaccine.

Keywords